PTO/SB/08a (02-09)

Approved for use through 03/31/2009. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE pond to a collection of information unlass it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to respond

Sub	stitute for form 1449/P1	го		Complete if Known		
				Application Number	10/524,724	
IN	<b>IFORMATIC</b>	ON DIS	CLOSURE	Filing Date	February 16, 2005	
S	TATEMEN1	ΓBY AI	PPLICANT	First Named Inventor	Matthew G. Dunckley	
				Art Unit	1635	
	(Use as many	sheets as n	ecessary)	Examiner Name	J. J. Zara	
Sheet	1	of	2	Attomey Docket Number	E072 1050.1	

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if Innown)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>		
	•							

	to the second se	
Examiner	Date	
LAGITIMO	Date	
Signature	Considered	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance end not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents et <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Stendard ST.3). ⁴ For Japanese patent documents, tha indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁴ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (02-09)

Approved for use through 03/31/2009, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sul	bstitute for form 1449/PTO			Complete if Known		
				Application Number	10/524,724	
11	NFORMATION	1 DI	SCLOSURE	Filing Date	February 16, 2005	
l s	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Matthew G. Dunckley	
				Art Unit	1635	
	(Use as many she	eets as	necessary)	Examiner Name	J. J. Zara	
Sheet	2	of	2	Attorney Docket Number	E072 1050.1	

Examiner Cite Initials No.1					
/J.Z./	1	BAUGHAN et al., "Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy," HMG Advance Access published February 19, 2009, Pages 1-48, Published by Oxford University Press.			
B0000000000	2	LACERRA et al., "Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients," Proc. Natl. Acad. Sci. (PNAS) USA 97(17): 9591-9596 (2000).			
000000000000000000000000000000000000000	3	SAZANI et al., "Systemically delivered antisense oligomers upregulate gene expression in mouse tissues". Nat Biotechnol. 20(12): 1228-33 (2002).			
***************************************	4	SUWANMANEE et al., "Restoration of human beta-globin gene expression in murine and human IVS2-654 thalassemic erythroid cells by free uptake of antisense oligonucleotides," Mol. Pharmacol. 62(3):545-53 (2002).			
999	5	WIRTH B., "Spinal muscular atrophy: state-of-the-art and therapeutic perspectives," ALS and Other Motor Neuron Disorders 3: 87-95 (2002).			
V	6	ZHANG et al., "Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis," Nature Biotechnology 18: 862-867 (2000).			

Examiner	/ Jano Zara/	Date	02/24/2010
Signature	/Jaile Laia/	Considered	02/24/2010

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). 2Applicant is to place a check mark here if English language Translation is attached.